- Home
- SPRO vs DYAI Comparison
SPRO vs DYAI Comparison
Compare SPRO & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- DYAI
- Stock Information
- Founded
- SPRO 2013
- DYAI 1979
- Country
- SPRO United States
- DYAI United States
- Employees
- SPRO N/A
- DYAI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPRO Health Care
- DYAI Health Care
- Exchange
- SPRO Nasdaq
- DYAI Nasdaq
- Market Cap
- SPRO 45.7M
- DYAI 54.4M
- IPO Year
- SPRO 2017
- DYAI 2004
- Fundamental
- Price
- SPRO $0.69
- DYAI $1.38
- Analyst Decision
- SPRO Buy
- DYAI Strong Buy
- Analyst Count
- SPRO 4
- DYAI 1
- Target Price
- SPRO $5.00
- DYAI $6.00
- AVG Volume (30 Days)
- SPRO 121.5K
- DYAI 59.9K
- Earning Date
- SPRO 03-27-2025
- DYAI 03-26-2025
- Dividend Yield
- SPRO N/A
- DYAI N/A
- EPS Growth
- SPRO N/A
- DYAI N/A
- EPS
- SPRO N/A
- DYAI N/A
- Revenue
- SPRO $47,977,000.00
- DYAI $3,495,389.00
- Revenue This Year
- SPRO N/A
- DYAI $51.30
- Revenue Next Year
- SPRO N/A
- DYAI $73.26
- P/E Ratio
- SPRO N/A
- DYAI N/A
- Revenue Growth
- SPRO N/A
- DYAI 20.58
- 52 Week Low
- SPRO $0.68
- DYAI $0.93
- 52 Week High
- SPRO $1.81
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- SPRO 35.60
- DYAI 46.47
- Support Level
- SPRO $0.75
- DYAI $1.29
- Resistance Level
- SPRO $0.80
- DYAI $1.45
- Average True Range (ATR)
- SPRO 0.05
- DYAI 0.10
- MACD
- SPRO -0.01
- DYAI 0.00
- Stochastic Oscillator
- SPRO 5.83
- DYAI 41.38
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.